

CROATIAN JOURNAL OF ONCOLOGY

# LIBRI ONCOLOGICI



LIBRI ONCOL. ISSN 0300-8142  
UDK 616 – 006

2024 Vol. 52 Suppl. 1

VOLUMEN 52

NUMERUS suppl 1

# **LIBRI ONCOLOGICI**

**CROATIAN JOURNAL OF ONCOLOGY**

Zagreb, 2024

CROATIAN JOURNAL OF ONCOLOGY  
LIBRI ONCOLOGICI

**Publisher**

Sestre milosrdnice University Hospital Center  
University Hospital for Tumors, Zagreb, Croatia

**Editor-in-Chief**

Ivan Milas

**Editors**

Lidija Beketić-Orešković, Antonio Juretić, Božena Šarčević

**Associate Editors**

Iva Kirac – Experimental Research  
Mladen Stanec – Surgical Oncology  
Robert Šeparović – Medical Oncology  
Martina Mikulandra – Radiation Oncology

**Technical Editor**

Anica Vrdoljak

**Editorial Board**

Gordana Brozović, Sanda Bubanović, Željko Herceg, Ljiljana Mayer, Aleksandar Milenović, Melita Perić Balja, Mario Puljiz, Snježana Ramić, Vesna Ramljak, Andrej Roth, Danko Velimir Vrdoljak, Tiha Vučemilo

**Editorial Council**

M. Ćorić (Zagreb, Croatia), T. Čufer (Ljubljana, Slovenia), N. Đaković (Zagreb, Croatia), M. Gamulin (Zagreb, Croatia), D. Kalafatić (Zagreb, Croatia), S. Kaštelan (Zagreb, Croatia), Ž. Kaštelan (Zagreb, Croatia), M. Klarica (Zagreb, Croatia), D. Krleža (Dublin, Ireland), J. Koeva-Balabanova (Sofia, Bulgaria), D. La Forgia (Bari, Italy), A. Lancia (Pavia, Italy), D. Marčinko (Zagreb, Croatia), A. Mrkonjić (Malmö, Sweden), S. Orešković (Zagreb, Croatia), P. Ozretić (Zagreb, Croatia), S.Ž. Pavletić (Bethesda, USA), I. Tomaš (Osijek, Croatia), D. Vagić (Zagreb, Croatia), E. Vrdoljak (Split, Croatia), Ž. Vujašković (Baltimore, USA)

---

**This journal is indexed or abstracted by:**  
**SCOPUS, DOAJ, HRČAK, Scilit Basel, CrossReff, Index Copernicus, Google Scholar,**  
**ResearchGate, JournalsPedia**

---

Editorial Office:

LIBRI ONCOLOGICI, Ilica 197, 10 000 Zagreb, Croatia

Phone (385 1) 37 83 522

Web site: <http://hrcak.srce.hr/libri-oncologici>

e-mail: [libri.oncologici@kbcsm.hr](mailto:libri.oncologici@kbcsm.hr)

The journal is published three times a year. Orders can be placed directly to the Editorial Office.

Price per copy 10 €. Annual subscription rates in Croatia: 45 € + VAT for institutions, 21 € + VAT for individuals and 10 € + VAT for students, to be remitted with Hrvatska narodna banka, account HR12 1001 0051 8630 0016 0 Ref.No.HR65 7129-051-26395 (for LIBRI ONCOLOGICI).

Annual subscription abroad - equivalent of US\$ 50 to be paid into the foreign currency account with Hrvatska narodna banka, IBAN: HR12 1001 0051 8630 0016 0 (Ref.No.HR65 7129-051-26395), BIC code: NBHRHR2XXXX (for LIBRI ONCOLOGICI)

Cover Design: Osman Berberović

Typesetting and printed by DENONA d.o.o., Zagreb

Publishing of Libri Oncologici is supported by the Ministry of Science and education of the Republic Croatia



# 17. HRVATSKI ONKOLOŠKI KONGRES

11.04.-14.04.2024. | Amadria Park | Šibenik



# 17. HRVATSKI ONKOLOŠKI KONGRES 17<sup>th</sup> CROATIAN ONCOLOGY CONGRESS

11. 04. - 14. 04. 2024.  
Šibenik, Amadria Park

Supplement editors:  
**Eduard Vrdoljak and Marijana Jazvić**

Šibenik, Croatia  
April, 2024

## ORGANIZER

Hrvatsko onkološko društvo - Hrvatski liječnički zbor  
Croatian Society of Oncology

### Organizing committee:

*President:*

Eduard Vrdoljak

*Secretaries:*

Antonio Juretić, Ingrid Belac Lovasić

Lidija Beketić Orešković, Sestre milosrdnice UHC; Ana Frobe, Sestre milosrdnice UHC; Višnja Matković, UHC Zagreb; Miroslav Samaržija, UHC Zagreb; Mladen Solarić, UHC Zagreb; Stjepko Pleština, UHC Zagreb; Stipislav Jadrijević, CH Merkur; Nina Dabelić, Sestre milosrdnice UHC; Marijo Boban, UHC Split – Firule; Marko Zelić, UHC Rijeka; Snježana Tomić, UHC Split; Ante Ćorušić, UHC Zagreb; Martina Bašić Koretić, UHC Zagreb; Josipa Flam, UHC Osijek; Goran Golčić, UHC Rijeka; Marko Jakopović, UHC Zagreb – Jordanovac; Tomislav Omrčen, UHC Split – Firule; Boris Ružić, Sestre milosrdnice UHC; Mario Šekerija, Croatian National Cancer Registry; Inga Marjanović, UCH Mostar; Branka Petrić Miše, UHC Split; Marijana Jazvić, Sestre milosrdnice UHC; Jasna Radić, Sestre milosrdnice UHC; Ilijan Tomaš, Osijek UHC; Ivana Canjko Osijek UHC

### Sponsors and exhibitors:

Amgen

Astellas

AstraZeneca

Bausch Health

Bayer

Biocon

Elekta i Medicem servis

Ewopharma

Genesis Pharma

GlaxoSmithKline

Johnson & Johnson S.E.

Lilly

Mediatelly

Medis Adria

Medison Pharma

Merck

Merck Sharp & Dohme

Novartis

Oktal Pharma

Pfizer

Pharma Maac

Pharmabiz

Roche

Sandoz

Servier

## CONTENTS

### ORAL PRESENTATIONS

Anuška Budisavljević

**S1 - The role of immune checkpoint inhibitors in treatment of triple negative breast cancer . . . . . 3**

Mirela Šambić Penc, Maja Kovač Barić, Josipa Flam, Zdravka Krivdić Dupan, Silva Guljaš, Luka Perić, Tara Cvijić, Dino Belić, Sebastijan Spajić, Dominik Seletković, Ivana Canjko

**S2 – Neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer . . . . . 5**

Ivana Canjko, Maja Kovač Barić, Luka Perić, Zdravka Krivdić Dupan, Tara Cvijić, Sebastijan Spajić, Dominik Seletković, Dino Belić, Josipa Flam, Mirela Šambić-Penc

**S3 – Integration of SBRT and immunotherapy in the treatment of early stage lung cancer . . . . . 8**

Josipa Flam, Mirela Šambić Penc, Ivana Canjko, Ilijan Tomaš, Luka Perić, Dino Belić, Sebastijan Spajić, Darko Kotromanović, Tara Cvijić, Maja Kovač Barić

**S4 – Immunotherapy in treatment of advanced gastric and EGJ cancer . . . . . 9**

Kristina Katić

**S5 – Targeted therapy in the treatment of gynecological cancers . . . . . 11**

Vesna Bišof

**S6 – Locally advanced pancreatic cancer – Multidisciplinary on the test . . . . . 13**

Krešimir Tomić

**S7 – Immunotherapy in gynecological cancers . . . . . 15**

Martina Bašić Koretić

**S8 - Importance of prognostic and predictive tests in adjuvant breast cancer therapy . 16**

Jure Murgić, Marijana Jazvić

**S9 – Antibody-drug conjugates in the treatment of bladder cancer . . . . . 18**

Jasna Radić, Jasmina Marić Brozić, Neva Purgar Levarda, Mirela Kekić, Marko Jakopović, Ivana Canjko, Suzana Mladinov, Iva Pavković, Maja Kolak, Chiara Ćelić, Ljubica Vazdar, Ivana Mikolašević, Marijo Boban, Eduard Vrdoljak, Ana Fróbe

**S10 – Treatment of unresectable stage III non-small cell lung cancer in Croatia . . . . . 20**

Marijo Boban

**S11 – Open questions in targeted therapy of non-small cell lung cancer . . . . . 22**

Nina Dabelić, Jasmina Marić Brozić, Marin Šunjić, Kristina Urch, Ana Fröbe <b>S12 – Neoadjuvant melanoma treatment – The imminent future</b> . . . . .	24
Marija Ban <b>S13 – Breast cancer and pregnancy</b> . . . . .	27

POSTER PRESENTATIONS

Zdravka Krivdić Dupan, Silva Guljaš, Mirela Šambić Penc, Ivana Canjko, Luka Perić, Dino Belić, Sebastijan Spajić, Petra Šmit Taka, Tamer Salha, Ana Marija Kovač Pejić, Tara Cvijić <b>P1 - Radiological and clinical findings of immunotherapy complications in patients treated with pemrolizumab in the first-line treatment of metastatic lung cancer in patients with PD-L1 expression &gt;0%</b> . . . . .	31
Vesna Bišof, Florian Lordick, Manish Shah A, Shitara Kohei, Ajani Jaffer A, Bang Yung Jue, Peter Enzinger, David Ilson, Eric Van Cutsem, Javier Gallego Plazas, Jing Huang, Shen Lin, Oh Sang Cheul, Sunpaweravong Patrapim, Soo Hoo Hwoei Fen, Turk Haci Mehmet, Park Jung Wook, Moran Diarmuid, Bhattacharya Pranob, Cao Ying, Xu Rui Hua <b>P2 - Updated efficacy and safety results from phase 3 glow study evaluating zolbetuximab + CAPOX as first-line treatment for patients with claudin 18 isoform 2-positive, human epidermal growth factor receptor 2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma</b> . . . . .	33
Damir Vučinić, Manda Švabić-Kolacio, Milan Radojčić, Nevena Obajdin, David Rajlić, Đeni Smilović-Radojčić <b>P3 - Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: a single center experience</b> . . . . .	35
Matea Grubišić-Čabo, Marinko Bošnjak, Lana Jajac Bručić, Miran Bujas, Filip Grubišić-Čabo, Marin Paić <b>P4 - Poor dental status as a factor which prevents prescription of bone antiresorptive agents in patients with metastatic castration-resistant prostatic cancer- single center experience</b> . . . . .	36
Ana Glavan Ćosić, Tihana Salopek, Ivona Jerković, Ivona Badovinac, Laura Novak, Doris Kolovrat, Iva Skočilić, Jasna Marušić, Ani Mihaljević Ferari, Damir Vučinić, Ivana Mikolašević <b>P5 - Is EAT-10 in correlation with BIA parameters useful to assess swallowing during the radiotherapy in patients with head and neck cancer? A pilot study</b> . . . . .	37
Ivona Jerković, Tihana Salopek, Damir Vučinić, Doris Kolovrat, Ana Glavan Ćosić, Ivona Badovinac, Laura Novak, Iva Skočilić, Jasna Marušić, Ani Mihaljević Ferari, Ivana Mikolašević <b>P6 - Bioelectric impedance analysis parameters as predictors of side effects in patients treated with chemotherapy</b> . . . . .	39
Lea Ledinski, Petra Jakši, Nikolina Lonjak, Mihaela Trajbar, Petra Linarić, Ana Tečić Vuger <b>P7 - Abemaciclib-associated diarrhea and dose modification in patients with early breast cancer</b> . . . . .	40

Mirela Kekić, Jure Murgić, Marijana Jazvić, Angela Prgomet Sečan, Zrna Antunac Golubić, Milena Gnjidić, Marija Gamulin, Tomislav Omrčen, Dag Zahirović, Mirela Šambić Penc, Maja Drežnjak Madunić, Ivo Dilber, Mihaela Trajbar, Ljubica Vazdar, Robert Šeparović, Lana Jajac Bručić, Anuška Budisavljević, Ana Fröbe	
<b>P8 - Avelumab as maintenance after platinum-based chemotherapy for advanced urothelial cancer (AUC) – updated results from croatian uro-oncology collaborative group (CUOCG) . . . . .</b>	<b>41</b>
Petra Sertić, Karla Zekulić, Josipa Meštrović, Nikolina Lonjak, Andro Dolić, Lea Ledinsky, Mihaela Trajbar, Petra Jakšić, Aljoša Šikić, Ana Tečić Vuger	
<b>P9 - Cancer patients in Emergency Department – Single-institution experience . . . . .</b>	<b>43</b>
Ana Bjeliš, Marija Ban, Ante Strikić, Ivana Tica Sedlar, Ana Majić, Branka Petrić Miše	
<b>P10 - Clinical characteristics and outcomes of patients with luminal B subtypes of breast cancer treated with neoadjuvant therapy – single center experiences from University Hospital of Split . . . . .</b>	<b>44</b>
Hrvoje Brčić, Jasna Radić, Jasmina Marić-Brozić, Jure Murgić, Neva Purgar Levarda, Ana Fröbe	
<b>P11 - Clinical outcomes of patients with metastatic non-small cell lung cancer treated with pembrolizumab - Experience of one center . . . . .</b>	<b>45</b>
Hrvoje Brčić, Jure Murgić, Blanka Jakšić, Marin Prpić, Angela Prgomet Sečan, Ana Fröbe	
<b>P12 - Comparison of hypofractionation and standard fractionation for salvage radiotherapy in patients with biochemical recurrence or PSA persistence following prostatectomy: single institution analysis (N=379) . . . . .</b>	<b>46</b>
Doris Kolovrat, Damir Vučinić, Maja Kolak, Manda Švabić, Ivona Jerković, Laura Novak, Ivona Badovinac, Tihana Salopek, Eleonora Cini Tešar, Sanja Ropac, Jasna Marušić, Iva Skočilić, Ana Glavan Ćosić, Ivana Mikolašević	
<b>P13 - Constraint dose effect on the thyroid gland in the context of development of non-alcoholic fatty liver disease in patients with breast cancer . . . . .</b>	<b>48</b>
Katarina Antunac, Klara Bubnić, Martina Mikulandra, Lidija Beketić-Orešković	
<b>P14 - Correlation of LVEF drop and cardiac radiation doses in patients with left breast cancer undergoing hypofractionated adjuvant radiotherapy with concurrent HER2 targeted therapy . . . . .</b>	<b>49</b>
Ana Majić, Branka Petrić Miše, Ante Strikić, Ivana Tica Sedlar, Marija Ban, Darijo Hrepić, Eduard Vrdoljak	
<b>P15 - Effect of neoadjuvant endocrine therapy (NET) duration on changes in clinical response rate . . . . .</b>	<b>51</b>
Marin Golčić, Damir Vučinić, Iva Skočilić, Renata Dobrila-Dintinjana, Maja Kolak, Ivona Jerković, Eleonora Cini-Tešar, Ani Mihaljević-Ferari, Arnela Redžović, Jasna Marušić, Doris Kolovrat, Ivana Mikolašević	
<b>P16 - Evaluation of the factors affecting survival in elderly lung cancer patients treated with immunotherapy . . . . .</b>	<b>52</b>



Mirela Kekić, Jure Murgić, Marijana Jazvić, Željko Soldić, Ana Fröbe, Mario Šekerija <b>P17 - Evolution of breast cancer management and survival outcomes: two decades of change in large tertiary institution . . . . .</b>	54
Luka Perić, Josipa Flam, Ilijan Tomaš, Sebastijan Spajić, Ivana Canjko, Mirela Šambić Penc, Tara Cvijić, Darko Kotromanović, Dominik Seletković, Dino Belić <b>P18 - Experiences of KBC Osijek with patients who were diagnosed with breast cancer in 2021 and 2022 and their response based on the type of tumour after receiving neoadjuvant therapy . . . . .</b>	55
Dora Čerina Pavlinović, Jelena Šuto Pavičić, Marija Pancirov, Bisera Mamić, Katarina Doko, Iva Čutura, Vid Duplančić, Ilijan Tomaš, Robert Šeparović, Stjepko Pleština, Eduard Vrdoljak <b>P19 - Feasibility of comprehensive genomic profiling (CGP) in personalized approach to patients with metastatic colorectal cancer – results from the first two years of testing in Croatia. . . . .</b>	57
Luka Rogoznica, Matea Buljubašić Franić, Joško Bezić, Branka Petrić Miše <b>P20 - Impact of COVID-19 on melanoma diagnosis in University Hospital Split . . . . .</b>	58
Dora Čerina Pavlinović, Natalija Dedić Plavetić, Ingrid Belac Lovasić, Robert Šeparović, Josipa Flam, Marija Pancirov, Jelena Šuto Pavičić, Bisera Mamić, Žarko Bajić, Snježana Tomić, Eduard Vrdoljak <b>P21 - Impact of specific type of PIK3CA mutation on disease recurrence in patients with HR+, HER2- tumors treated with adjuvant hormonal therapy - results from Croatia. . . . .</b>	60
Doris Kolovrat, Damir Vučinić, Ivona Jerković, Iva Skočilić, Maja Kolak, Eleonora Cini Tešar, Sanja Ropac, Tihana Salopek, Ana Glavan Ćosić, Lana Bolf Perić, Jasna Marušić, Laura Novak, Ivana Mikolašević <b>P22 - Influence of hormonal therapy on nutrition and metabolic parameter as well as the development of liver steatosis and inflammation in breast cancer patience . . . . .</b>	61
Maja Erceg Tušek, Ljiljana Vukota <b>P23 - My survivorship plan - what works for me? . . . . .</b>	62
Mirela Kekić, Jure Murgić, Marijana Jazvić, Angela Prgomet Sečan, Monika Ulamec, Ivo Dilber, Katarina Vilović, Ivan Pezelj, Igor Tomašković, Adelina Hrkać, Slaven Ovčariček, Pero Bokarica, Lana Jajac Bručić, Maja Drežnjak Madunić, Mirela Šambić Penc, Toni Boban, Žana Saratlija, Marijan Šitum, Tihana Boraska Jelavić, Tomislav Omrčen, Ana Fröbe <b>P24 - Neoadjuvant or induction chemotherapy (N/IC) for bladder cancer: updated real world experience on 157 patients – results from Croatian uro-oncology network . . . . .</b>	64
Kristina Katić, Višnja Matković, Goran Vujić, Sania Kuzmac, Marija Milković Periša <b>P25 - Olaparib first-line maintenance therapy for patients with newly diagnosed, advanced high-grade serous ovarian cancer and a BRCA mutation: an one institution experience . . . . .</b>	66

Ana Bjeliš, Marija Ban, Ante Strikić, Ivana Tica Sedlar, Ana Majić, Snježana Tomić, Branka Petrić Miše	
<b>P26 - Pathological characteristics of luminal B subtype of breast cancer before and after neoadjuvant therapy - single center experiences from University Hospital of Split . . . . .</b>	<b>67</b>
Dora Čerina Pavlinović, Jelena Šuto Pavičić, Marija Pancirov, Bisera Mamić, Katarina Doko, Iva Čutura, Vid Duplančić, Eduard Vrdoljak	
<b>P27 - Position of comprehensive genomic profiling (CGP) in the management of metastatic gastric cancer. Real world data among Croatian patients in the first two years of testing . . . . .</b>	<b>68</b>
Tomislav Omrčen, Dario Hrepić, Ana Barić Žižić	
<b>P28 - Radium-223 in patients with metastatic castration-resistant prostate cancer - retrospective analysis of the treatment experience at the University Hospital Split . .</b>	<b>69</b>
Krešimir Tomić, Ema Voloder, Gordana Berić Jozić, Maja Pezer Naletilić, Sanda Čale, Marija Perić, Dragana Miletić, Semir Vranić, Eduard Vrdoljak	
<b>P29 - Real-world outcomes of chemotherapy in first-line treatment for extensive small cell lung cancer: a single center experience from Bosnia and Herzegovina . . . .</b>	<b>70</b>
Marin Šunjić, Jasmina Marić Brozić, Nina Dabelić, Jure Murgić, Ana Frobe	
<b>P30 - Results of treatment with PD-1 inhibitor pembrolizumab in patients with metastatic melanoma at UHC Sestre milosrdnice Zagreb . . . . .</b>	<b>72</b>
Dora Čerina, Jelena Šuto Pavičić, Marija Pancirov, Bisera Mamić, Katarina Doko, Iva Čutura, Vid Duplančić, Ivana Canjko, Robert Šeparović, Belac Ingrid Lovasić, Kristina Katić, Blanka Jakšić, Stjepko Pleština, Eduard Vrdoljak	
<b>P31 - Role of comprehensive genomic profiling (CGP) in the personalized gynecological cancer care. Real world data on a national level . . .</b>	<b>73</b>
Sebastijan Spajić, Maja Drežnjak Madunić, Ilijan Tomaš, Mirela Šambić Penc, Maja Kovač Barić, Dino Belić, Luka Perić, Dora Mesarić, Tara Cvijić, Suzana Erić	
<b>P32 - Safety and efficacy of immune checkpoint inhibitors in patients with renal cancer on hemodialysis; a single centre experience . . . . .</b>	<b>75</b>
Joško Bezić, Toni Čeprnja, Branka Petrić Miše, Maja Pavić	
<b>P33 - Spectrum of BRAF mutations in skin melanomas in the Dalmatian region of Croatia . . . . .</b>	<b>76</b>
Silva Guljaš, Zdravka Krivdić Dupan, Salha Tamer, Petra Šmit Takač, Mirela Šambić Penc, Ivana Canjko	
<b>P34 - Spectrum of true and false positive radiological imaging findings in lung screening programe at UHC Osijek . . . . .</b>	<b>77</b>
Sebastijan Spajić, Luka Perić, Josipa Flam, Ilijan Tomaš, Dino Belić, Ivana Canjko, Mirela Šambić, Darko Kotromanović, Zdravka Krivdić Dupan, Dominik Seletković	
<b>P35 - Systemic immune-inflammation index (SII) as a predictive value for complete pathological response after neoadjuvant therapy in breast cancer . . . . .</b>	<b>79</b>

Dino Belić, Josipa Flam, Mirela Šambić Penc, Sebastijan Spajić, Luka Perić, Ilijan Tomaš, Zdravka Krivdić Dupan, Robert Rončević, Irena Zagorac, Andreja Vukoja, Vedrana Hertl, Mladen Kasabašić	
<b>P36 - The reliability of preoperative ultrasound evaluation of axillary lymph nodes in patients with breast cancer . . . . .</b>	<b>80</b>
Ana Majić, Branka Petrić Miše, Ante Strikić, Ivana Tica Sedlar, Marija Ban, Darijo Hrepić, Eduard Vrdoljak	
<b>P37 - Treatment induced changes of KI67 level in neoadjuvant hormonal therapy with fulvestrant and aromatase inhibitors in patients with locally advanced ER+, HER2- early breast cancer . . . . .</b>	<b>81</b>
Krešimir Jemrić, Josipa Rajčić, Sanja Vušković, Spomenka Mikuš, Majana Soče, Vesna Bišof	
<b>P38 - Treatment of primary salivary gland malignancies - 12-year single institution experience . . . . .</b>	<b>83</b>
Ani Mihaljević Ferari, Iva Skočilić, Ivona Badovinac, Laura Novak, Jasna Marušić, Anita Beg <sup>1</sup> , Nevena Polić, Damir Vučinić, Tihana Salopek, Ivona Jerković, Doris Kolovrat, Renata Dobrila-Dintinjana, Ivana Mikolašević	
<b>P39 - Treatment of sarcopenia in elderly cancer patients by specific farmaconutrient - prospective, randomized study . . . . .</b>	<b>84</b>
Tihana Pavić, Petra Dželalija, Krešimir Jemrić, Slaven Stanojlović, Lana Ljubičić, Vesna Bišof, Lea Galunić Bilić	
<b>P40 - Treatment outcomes and toxicity in locally advanced non-small cell lung cancer patients undergoing radical radiotherapy: a single-centre retrospective analysis . . . .</b>	<b>85</b>
Tara Cvijić, Ivana Canjko, Ilijan Tomaš, Mirela Šambić Penc, Josipa Flam, Luka Perić, Darko Kotromanović, Zdravka Krivdić Dupan, Suzana Mimica	
<b>P41 - Treatment outcomes of ALK positive metastatic non-small cell lung cancer – A small center experience . . . . .</b>	<b>87</b>
Darko Kotromanović, Ivana Kotromanović Šimić, Tara Cvijić, Luka Perić, Josipa Flam, Suzana Erić, Zdenka Kotromanović, Sebastijan Spajić, Dominik Seletković, Ilijan Tomaš	
<b>P42 - Treatment of adjuvant melanoma in KBC Osijek - Experience of one center . . . .</b>	<b>88</b>
Ivan Babić	
<b>P43 - The use of tumor free distance as prognostic factor for five-year survival in endometrial cancer . . . . .</b>	<b>89</b>
Žana Saratlija, Mario Duvnjak, Hrvoje Stipančević, ANTE STRIKIĆ, Luka Jukica	
<b>P44 - Radiation-induced cystitis treated with hyperbaric oxygen therapy in University Hospital Split . . . . .</b>	<b>90</b>
<b>AUTHOR INDEX . . . . .</b>	<b>91</b>